Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01591044 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
A Phase 2 study, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
NCT01591044 is a Phase 2 study that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 301 participants.
The verdict
NCT01591044, a Phase 2 study, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
Interventions
- DRUG Placebo
- DRUG R940343 1mg
- DRUG R940343 2mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01591044
The ClinicalTrials.gov registry entry for NCT01591044 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01591044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01591044 about?
NCT01591044 is a clinical study titled "A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma". The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
What is the current status of trial NCT01591044?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2012-07. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01591044?
The interventions under investigation include: Placebo (DRUG), R940343 1mg (DRUG), R940343 2mg (DRUG).
Who is sponsoring clinical trial NCT01591044?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.